Related Experiment Video
Updated: May 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
RBM15/IGF2BP2-PTPRH m6A regulatory axis in non-small cell lung cancer
Keyue Qiu1,2, Xiaoxiao Zheng3, Hongxiang Li1,2
1Department of Thoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, 315000, China.
This study reveals a new mechanism where RBM15 and IGF2BP2 stabilize PTPRH mRNA via m6A modification, driving non-small cell lung cancer (NSCLC) progression. This RBM15/IGF2BP2-PTPRH axis presents a potential therapeutic target for NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Non-small cell lung cancer (NSCLC) is a major global cancer-related mortality cause.
- Identifying novel molecular drivers and therapeutic targets for NSCLC is critical.
- This research focuses on protein tyrosine phosphatase receptor type H (PTPRH) and its epitranscriptomic regulation in NSCLC.
Purpose of the Study:
- To investigate the role and regulation of PTPRH in NSCLC.
- To elucidate the epitranscriptomic mechanism involving N6-methyladenosine (m6A) modification in PTPRH regulation.
- To identify the RBM15/IGF2BP2-PTPRH axis as a potential therapeutic target.
Main Methods:
- Integrated analysis of The Cancer Genome Atlas and Gene Expression Omnibus datasets.
- Validation of PTPRH expression in clinical NSCLC specimens and correlation with clinicopathological features.
- In vitro and in vivo functional assays to assess PTPRH effects on tumor progression.
- Investigation of m6A modification, RBM15, and IGF2BP2 roles in PTPRH mRNA stability.
Main Results:
- PTPRH is overexpressed in NSCLC and correlates with poor prognosis.
- PTPRH promotes proliferation, migration, invasion, and angiogenesis, while inhibiting apoptosis.
- RBM15-mediated m6A modification and IGF2BP2 binding stabilize PTPRH mRNA, driving oncogenic functions.
Conclusions:
- A novel RBM15/IGF2BP2-PTPRH axis regulates PTPRH mRNA stability via m6A modification in NSCLC.
- This axis promotes NSCLC progression and represents a potential therapeutic target.
- The study enhances understanding of post-transcriptional regulation in lung cancer.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Negative Regulator Molecules
TGF - β Signaling Pathway